Pharmaceuticals, Biotechnology and Life Sciences
The European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, Bristol Myers Squibb said Friday.
CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to announce the signing of a strategic partnership with Viking Therapeutics, a clinical stage company focused on developing novel therapies for metabolic and endocrine disorders.
Clasado Biosciences, a developer of prebiotic ingredients and products for the gut microbiome, has announced its Bimuno GOS shows a…
Valneva SE, a specialty vaccine company, said on Friday that the Committee for Medicinal Products for Human Use (CHMP) of…
Moderna reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28), and expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion.
Barentz, a leading global specialty ingredients solution provider, has appointed Esther Veninga as Chief Financial Officer (CFO) and as a member of the Board.
JuliaHub is doubling its investment in the pharmaceutical sector, leveraging JuliaHub’s new-and-improved CFR Part 11-compliant pharmaceutical platform. The company said…
Lindis Biotech GmbH, a clinical stage biopharmaceutical company, and Pharmanovia, a global pharmaceutical company, announced Thursday that catumaxomab has received marketing authorisation from the European Commission (EC), making the drug the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe.
Axplora, a global leader in API small molecule and ADC manufacturing, has announced a landmark €50 million investment in its Mourenx site in Southwest France, securing its position as a key player in the fight against cardiovascular and metabolic diseases.
Global biotechnology company CSL Behring announced on Friday the four-year results from the pivotal HOPE-B study confirming the long-term durability…